Shares of Baxter International (BAX) Sees Large Outflow of Money

Baxter International (BAX) : The total money flow in Baxter International (BAX) was negative ($21.23 million), which signals selling by the traders on Thursdays session. They trimmed their holdings by selling the stock on downticks to the tune of $33.89 million. In comparison, the inflow of money into the stock on upticks was $12.66 million. The uptick to downtick ratio was 0.37. Similarly, the block trades show selling by large traders on strength. The value of stocks sold down on downtick was $21.97 million. The value of transactions on uptick was $0.64 million. The negative money flow of ($21.33 million) confirms the selling in Baxter International (BAX) on strength. The uptick to downtick ratio of block trades was 0.03. Baxter International (BAX) gained $0.13 at $46.12, a gain of 0.28% over the previous days close. However, the stock registered 1.47% in the week.


Baxter International (BAX) : 6 investment research analysts covering Baxter International (BAX) have an average price target of $48.83 for the near short term. The highest target price given by the Brokerage Firm to the stock is $60 and the lowest target is $46 for the short term. Analysts expect the variance to be within $5.49 of the average price. The stock has recorded a 20-day Moving Average of 3.27% and the 50-Day Moving Average is 3.95%.

Baxter International (NYSE:BAX): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $45.92 and $45.86 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $46.36. The buying momentum continued till the end and the stock did not give up its gains. It closed at $46.12, notching a gain of 0.28% for the day. The total traded volume was 2,485,362 . The stock had closed at $45.99 on the previous day.

Baxter International Inc. (Baxter) is a diversified healthcare company. The Company operates in two segments: BioScience segment, which include three commercial franchises: Hemophilia, BioTherapeutics and BioSurgery, and Medical Products segment, which include four commercial franchises: Fluid Systems, Renal, Specialty Pharmaceuticals and BioPharma Solutions. Its BioScience processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions, and biosurgery products. Its Medical Products manufactures intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, infusion pumps and inhalation anesthetics. Its products are used in hospitals, kidney dialysis centers and nursing homes, among others.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.